BriaCell plans Bria-OTS+ clinical entry in metastatic breast, prostate cancers later this year
PUBT · 04/21 11:31
Share
Listen to the news
- BriaCell presented positive preclinical data on Bria-OTS+ at 2026 AACR Annual Meeting on April 21, 2026.
- Bria-OTS+ showed broad anti-cancer activity in lab models, activating immune responses with durable tumor-killing effects.
- Program advanced toward first clinical entry in metastatic breast cancer and prostate cancer later in 2026.
- Company outlined plans to expand Bria-OTS+ into lung cancer and melanoma indications in 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604210730PRIMZONEFULLFEED9693580) on April 21, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending